Hook + thesis
Alumis is no longer a backyard biotech speculation. After two positive Phase 3 ONWARD readouts for envudeucitinib in plaque psoriasis announced on 03/28/2026, the market has re-priced the company: the stock now sits above $25 and market capitalization is roughly $3.2 billion. Those results - PASI 90 rates of 68.0% and 62.1% and PASI 100 of ~40% - are the kind of numbers that can carry a newly launched oral TYK2 inhibitor into the top tier of dermatology medicines if regulatory and commercial execution follow.
My thesis: envudeucitinib appears to be the primary value driver for ALMS over the next 6-12 months. I think there is a path for meaningful upside between now and the company’s next major catalysts (pivotal lupus data expected in Q3 and an NDA submission planned for Q4 2026). That path is not free of risk — valuation is elevated and the space is crowded — but I prefer a tactical long exposure with a defined entry, stop and target to capture a likely clinical-driven rerating while limiting downside if the story stalls.
What Alumis does and why the market should care
Alumis is a clinical-stage biopharmaceutical company focused on immune-mediated diseases. The company’s lead program, envudeucitinib, is an oral TYK2 inhibitor designed for inflammatory conditions such as moderate-to-severe plaque psoriasis and systemic lupus. The market cares because envudeucitinib's Phase 3 ONWARD results showed rapid and deep skin clearance (PASI 90 at Week 24 of 68.0% and 62.1% across two trials, with PASI 100 in the ~40% range). Those efficacy numbers — combined with reported early quality-of-life and itch improvements and a favorable safety profile — give the drug a clear product narrative versus oral alternatives.
Key numbers and financial picture
| Metric | Value |
|---|---|
| Current price | $25.56 |
| Market cap | $3.19B |
| Enterprise value | $3.10B |
| Cash reported (news) | $569.5M |
| Capital raise (01/08/2026) | 17.65M shares at $17.00 (~$300M gross) |
| EPS (TTM) | -$1.86 |
| Price / Book | ~5.58x |
| Free cash flow (recent) | -$377.0M |
| 52-week range | $2.80 - $30.60 |
Two things stand out. First, the company raised meaningful capital in early 2026 (an upsized offering priced at $17 on 01/08/2026 that generated roughly $300M gross), and public disclosures indicate cash on the balance sheet of about $569.5M. That gives Alumis a runway to advance late-stage programs and pursue an NDA submission, and has likely reduced near-term dilution risk.
Second, despite the cash cushion, valuations already embed high expectations: price-to-sales is extremely elevated and EPS is negative. In plain terms, the market has priced in successful filing, approval and at least a credible commercial launch. The question is whether envudeucitinib's clinical profile and upcoming data will justify that expectation.
Technical and market context
Momentum is supportive: the stock is trading above its 10-, 20- and 50-day moving averages (10-day SMA: $23.58; 50-day SMA: $23.13), RSI around 63, and MACD showing bullish momentum. Volume is material — two-week average volume ~1.45M — and short interest remains meaningful (most recent settlement shows ~11.07M shares short with days to cover near 13), which can amplify moves in either direction.
Catalysts to watch (next 3-9 months)
- Pivotal lupus data expected in Q3/2026 - this is a binary efficacy/safety readout that could materially change valuation.
- NDA submission planned for Q4/2026 for psoriasis - acceptance and potential review timelines will shape the commercial outlook.
- Analyst coverage and commercial partnering or pricing discussions following topline regulatory signals.
- Quarterly financials and updates on cash runway and commercialization planning - will confirm whether spending and commercialization investments are on track.
Valuation framing
At roughly $3.2B market cap and an enterprise value near $3.1B, Alumis is being valued as if envudeucitinib will become a significant product. That math is not irrational in biotech: a successful psoriasis launch that achieves even a few percent of the total market can justify a multi-billion-dollar market cap. But the stock currently reflects success across multiple milestones — approval and meaningful commercial uptake — and therefore has little margin for clinical or regulatory surprises.
If envudeucitinib merely matches competitors or encounters safety, pricing, or access headwinds, the rerating could be dramatic. Conversely, if the lupus data is positive and the NDA moves ahead without major hurdles, analysts and the market will reassign a much higher revenue multiple and the stock could re-test — and exceed — prior highs. This is asymmetric: big upside if a pipeline readout confirms broader utility; big downside if the program stalls.
Trade plan (actionable)
Direction: Long
Entry price: $25.56
Stop loss: $20.00
Target price: $45.00
Horizon: long term (180 trading days) - I want to hold through the pivotal lupus readout in Q3 and into the window for the planned NDA filing in Q4 2026. Both events are likely within the 46-180 trading day window and could drive a material re-rating.
Why this plan? Entry near $25.56 lets you participate immediately in the momentum that follows positive Phase 3 psoriasis data and the company’s improved balance sheet. The $20.00 stop limits downside to a roughly 22% drawdown from entry — painful but reasonable for a biotech with both binary catalysts and meaningful short interest. The $45.00 target reflects a rerating toward a commercial-stage multiple should the lupus readout and regulatory path remain constructive; hitting $45 would imply substantial confidence in a multi-indication pathway for envudeucitinib and reacceleration of growth expectations.
Position sizing and risk management
Treat ALMS as a high-risk biotech allocation. Capital allocated should be sized so that a full stop does not impair overall portfolio objectives. Be ready to tighten stops if headlines or interim data change the risk profile. Monitor short-volume prints and insider/large-holder activity (for example, Cormorant increased its stake in Q1 2026), since these can correlate with near-term volatility.
Risks and counterarguments
- Regulatory / clinical risk: Late-stage and pivotal trials can produce unexpected safety signals or fail to meet secondary endpoints. A negative lupus readout would likely trigger a rapid repricing down.
- Crowded competitive landscape: Over 90 companies are active in psoriasis drug development; new oral TYK2 and IL-23 options reduce market share potential and pressure pricing.
- Valuation risk: The market currently prices in success across multiple milestones. Any delay in the NDA, negative regulatory feedback, or slower-than-expected commercial planning would likely compress multiples sharply.
- Dilution / financing risk: The company completed a sizable equity offering in January 2026. While proceeds increase runway (cash ~$569.5M), future commercialization investments or setbacks could necessitate additional capital, diluting shareholders.
- Commercial execution risk: Clinical success does not guarantee pricing, reimbursement, or physician adoption - especially for a new oral class competing against established injectables and newer small molecules.
Counterargument to my thesis
One reasonable bearish view is that positive psoriasis data are already priced in — the stock is up materially and market cap reflects optimistic assumptions about multi-indication adoption. In that scenario, the potential upside from the lupus readout is limited relative to the downside if the trial misses or safety concerns emerge. For traders who prefer lower-volatility set-ups, the current price may not offer adequate asymmetry.
Conclusion and what would change my mind
Conclusion: I favor a controlled long into ALMS at $25.56 with a $20 stop and $45 target over a 180 trading day horizon. The rationale: strong Phase 3 psoriasis results, a healthy cash runway from a $17 offering that raised ~ $300M, and near-term binary catalysts (pivotal lupus data in Q3 and an NDA submission in Q4) that can materially re-rate the stock.
What would change my mind: any credible safety signal from ongoing psoriatic or lupus trials, explicit regulatory guidance that delays an NDA filing, or clear deterioration in cash runway/projection would push me to exit. Conversely, an unexpectedly strong lupus readout, timely regulatory engagement, or a strategic commercial partnership announced ahead of filing would increase conviction and justify adding to positions.
Actionable snapshot: Long ALMS at $25.56, stop $20.00, target $45.00, horizon long term (180 trading days). Size the position as part of a diversified biotech allocation and follow catalysts closely.